SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 /CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" ...
Q4 2025 Management View Richard A. Stewart, President, CEO & Executive Director, emphasized the company's transition from a clinical-stage to a commercially focused enterprise following the NDA ...
New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug ...
Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to ...
In life sciences, enterprise value only emerges when generative AI is treated as a business capability and embedded into ...
A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...
Seamless RAM-ZenQMS integration unifies asset, maintenance, calibration, and quality data to create a closed-loop, inspection-ready GMP environment ...
Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results